Test Price
2,800 AED✅ Home Collection Available
CAMTA1 Gene Genetic Test for Non-Progressive Cerebellar Ataxia with Intellectual Disability in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Comprehensive NGS Genetic Assessment
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 15189:2022 accredited Next Generation Sequencing (NGS) platform.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all Emirates.
- Clinical Guidance: In-depth post-test result interpretation provided telephonically by DHA-licensed medical geneticists.
- Insurance & Billing: Direct billing verification and insurance pre-approval handled via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced NGS-based CAMTA1 gene test identifies pathogenic and likely pathogenic variants responsible for non-progressive cerebellar ataxia with intellectual disability. By analyzing the complete coding region and splice sites, our test delivers a definitive molecular diagnosis, enabling early therapeutic intervention, accurate prognostic assessment, and informed family planning guidance.
| Parameter | Our Test (NGS CAMTA1 Full Gene) | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity; detects SNVs, indels, and CNVs | ~95% sensitivity; may miss large deletions or duplications |
| Method | NGS with advanced bioinformatic CNV calling | Sanger sequencing of exons only |
| Turnaround | 3–4 Weeks | 6–8 Weeks (fragmented testing) |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“A comprehensive NGS-based analysis for CAMTA1 is essential for accurately diagnosing non-progressive cerebellar ataxia with intellectual disability. Identifying the precise pathogenic variant allows for targeted family counseling and anticipatory clinical management. I strongly recommend that all results are reviewed within the context of a full neurological evaluation to ensure accurate clinical correlation and meaningful patient outcomes.”
Advisory & Medication Warning
Patients and caregivers are advised not to discontinue, modify, or initiate any prescribed neurological medication without direct consultation with their treating physician. Abrupt cessation of anti-epileptic or neurotropic therapies may provoke severe withdrawal seizures, neuropsychiatric instability, or acute neurological deterioration.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: This test is not indicated for prenatal diagnosis without prior confirmation of parental pathogenic variants. Sample acceptance requires a completed genetic counseling referral form.
- Absolute Contraindication: Do not submit cord blood, amniotic fluid, or chorionic villus samples for this assay without documented parental carrier status and explicit approval from the laboratory geneticist.
- Emergency Red Flags: New-onset seizures, sudden loss of ambulation, severe headache with vomiting (suggesting increased intracranial pressure), or acute psychiatric changes warrant immediate emergency department evaluation.
Patient FAQ & Clinical Guidance
1. What is the CAMTA1 gene test and who is it for?
This NGS-based test detects pathogenic CAMTA1 variants associated with non-progressive cerebellar ataxia and intellectual disability. It is recommended for children or adults presenting with unexplained early-onset ataxia, developmental delay, or a family history consistent with autosomal dominant inheritance of cerebellar dysfunction.
2. How accurate is the NGS methodology and what is the turnaround time?
Our NGS platform achieves 99.9% analytical sensitivity for single nucleotide variants, insertions, deletions, and copy number changes, significantly outperforming traditional Sanger sequencing. Standard turnaround time is 3–4 Weeks from the date of sample receipt at our Dubai Healthcare City laboratory.
3. Is home blood collection available across the UAE and how is privacy handled?
Yes. We offer VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection services available daily from 8 AM to 11 PM in all Emirates. All genetic data is fully anonymized, encrypted, and processed under strict adherence to UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and ISO 9001:2015 standards.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Privacy Assurance
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability
- ISO 15189:2022 & ISO 9001:2015 Accredited Quality Management Systems
- DHA Licensing Standards for Genetic Testing Facilities & Data Governance
Clinical & Logistical Metadata
| Test Name | CAMTA1 Full Gene Sequencing |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next Generation Sequencing (NGS) with Bioinformatic CNV Calling |
| ICD-10-CM Code | G11.2, F70 |
| LOINC Code | 94222-6 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians